Julián López Franco

Learn More
BACKGROUND Interleukin 2 (IL-2) and interleukin 12 (IL-12) are potent immunoregulatory cytokines that exhibit antitumor activity. Preliminary evidence suggests that combined administration of IL-2 and IL-12 may yield greater antitumor activity than that observed with either agent alone. PURPOSE We evaluated the ability of combination regimens of IL-2 and(More)
It has recently been shown that T-cell signal transduction molecules are altered in tumor-bearing mice. We have examined the expression of NF kappa B/Rel family proteins in T-cells from mice bearing Renca, a murine renal carcinoma. T-cells from Renca-bearing mice expressed undetectable levels of nuclear c-Rel, NF kappa B p65, and p50; however, two shorter(More)
Flavone-8-acetic acid plus recombinant human interleukin 2 is a successful antitumor therapy in mice bearing the Renca murine renal cell carcinoma. This report demonstrates that T cells, particularly CD8+ T cells, are critical for the generation of this response. Initial experiments examining T-cell signal transduction proteins demonstrated that T cells(More)
Administration of recombinant human interleukin-7 (rhIL-7) to mice increases the exportation of myeloid progenitors (colony-forming unit [CFU]-c and CFU-granulocyte erythroid megakaryocyte macrophage [CFU-GEMM]) from the bone marrow (BM) to peripheral organs, including blood, and also increases the number of primitive progenitor and stem cells in the(More)
  • 1